SE544963C2 - A traditional Chinese medicinal composition for treating rheumatism diseases - Google Patents
A traditional Chinese medicinal composition for treating rheumatism diseasesInfo
- Publication number
- SE544963C2 SE544963C2 SE2150549A SE2150549A SE544963C2 SE 544963 C2 SE544963 C2 SE 544963C2 SE 2150549 A SE2150549 A SE 2150549A SE 2150549 A SE2150549 A SE 2150549A SE 544963 C2 SE544963 C2 SE 544963C2
- Authority
- SE
- Sweden
- Prior art keywords
- parts
- traditional chinese
- chinese medicinal
- medicinal composition
- diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 16
- 208000025747 Rheumatic disease Diseases 0.000 claims abstract description 13
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 11
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract description 10
- 241001079007 Phellodendron chinense Species 0.000 claims abstract description 10
- 241000124033 Salix Species 0.000 claims abstract description 10
- 239000008713 qiang-huo Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000011230 binding agent Substances 0.000 abstract description 5
- 239000007884 disintegrant Substances 0.000 abstract description 5
- 239000000945 filler Substances 0.000 abstract description 4
- 229940126678 chinese medicines Drugs 0.000 abstract description 3
- 230000005923 long-lasting effect Effects 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 208000032023 Signs and Symptoms Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 241000382455 Angelica sinensis Species 0.000 description 3
- 241000893536 Epimedium Species 0.000 description 3
- 241000405911 Rehmannia glutinosa Species 0.000 description 3
- 241001506766 Xanthium Species 0.000 description 3
- 235000018905 epimedium Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 241000227129 Aconitum Species 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 206010053631 Bone swelling Diseases 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 241001261543 Orthriophis moellendorffi Species 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940080460 leflunomide 10 mg Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- -1 sodium starch Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Traffic Control Systems (AREA)
Abstract
The present invention provides a traditional Chinese medicinal composition consisting of by weight: 5-10 parts of Earthworm, 5-10 parts of Qianghuo, 5-10 parts of Caulis spatholobi, and 2-6 parts of Eucommia ulmoides, 2-6 parts of Phellodendron chinense, 2-6 parts of Willow branch, 1 -3 parts of filler, 1 -2 parts of disintegrant and 0.2-1 parts of binder, for use in the treatment of rheumatic diseases. Compared with the existing traditional Chinese medicinal composition for treating rheumatic diseases, the single Chinese medicines of the present invention have good compatibility and excellent therapeutic effect after compatibility. The pharmacodynamics of each component play a synergistic role, of which the clinically verified therapeutic effect is good, the curative effect is long-lasting, and the recurrence rate is low, it solves the problem of rheumatism diseases that cannot be cured for a long time.
Description
TECHNICAL FIELD
The present invention relates to a field of traditional Chinese medicine, in particular to a traditional Chinese medicinal composition for treating rheumatic diseases.
BACKGROUND
The rheumatism disease is the most common disease in our daily life, most of which are caused by joint diseases, which are interfered by factors such as environment, diet, disease and so on. lf the cause is not found in time, it may cause local pain, numbness, bone swelling and other symptoms. The common clinical diseases include rheumatoid arthritis, gout, ankylosing spondylitis, frozen shoulder, osteoarthritis, soft tissue injury, and the like.
According to statistics, about 2% of the global population is affected by rheumatic diseases. According to reports, rheumatoid diseases such as rheumatoid arthritis and ankylosing spondylitis have a high incidence in our country, about 0.4%. There are a large group of patients with a high disability rate, which seriously threatens people's health, and work and life, so it is called "cancer that can't die." ln recent years, whether it is traditional Chinese medicine or Western medicine, a lot of manpower and material resources have been invested in more in-depth research on rheumatic diseases, and a deep and comprehensive understanding of the disease has been achieved, such as the great progress on pathogenesis, detection methods and treatment methods. The main method of western medicine for rheumatism is non-steroidal medicine, but it has disadvantages such as large side effects, single effect and many contraindications. There is no specific treatment yet. Although Chinese medicine has gained some experience in the treatment of rheumatic diseases, there are few in-depth studies on its specific mechanism of action. Therefore, under the guidance of Chinese medicine theory, use of modern science and technology to conduct in-depth research on mechanism of Chinese medicine compound with definite curative effect, especially finding effective formulas of traditional Chinese medicinal compositions is the focus of current research.
At present, Chinese patent medicines for the treatment of rheumatic diseases focus on the treatment of cold-dampness blockage, blood congestion blockage. The current dosage forms are also relatively diverse, such as medicinal wine, tincture, ointment, granules, tablets, pills, etc., and most of its components are made of aconite, aconitum, horse money, and other Warm and yang products, and it is often compatible with earthworm, scorpion, centipede, pangolin, white flower snake, apiary and other insect
medicines that relieve pain. However, although the existing formulas have certain curative effects on rheumatic diseases, most of them have the problems of pungent heat, strong effects, and especially strong toxicity. For example, aconitum may cause aconitine poisoning, and strychnine may cause muscle cramps, convulsions and other problems. Therefore, although the existing formula may have a certain effect on treating rheumatic diseases.
ln the treatment of rheumatic diseases, although the existing western medicines and
Chinese patent medicines have certain curative effects, they cannot greatly solve the problems of the side effects of western medicines and the strong toxicity of existing Chinese patent medicines. The applicant has many years of research experience in this field, and has a wealth of research experience in the compatibility and compatibility of a variety of Chinese medicine single agents used in this field; after long-term research, it has been found that a more effective Chinese medicinal composition formula than the prior art, which can overcome the problems of poor compatibility and poor therapeutic effect of existing traditional Chinese medicinal composition.
SUMMARY
ln order to solve the problems of poor compatibility and poor therapeutic effect
between the components of the traditional Chinese medicinal composition for the treatment of rheumatism diseases, this application provides a Chinese medicinal composition comprising Chinese medicine single agents with good compatibility and a therapeutic effect after compatibility. The present invention provides the following technical solutions:
A traditional Chinese medicinal composition for of “ ' »diseases, ^ sfs-the traditional Chinese medicinal .šgby weight: 5-10 parts of Earthworm, 5-10 parts of
Qianghuo, 5-10 parts of Caulis spatholobi, and 2-6 parts of Eucommia ulmoides, 2-6 parts
i
of Phellodendron chinense, 2-6 parts of Willow branch.
Preferably, the traditional Chinese medicinal composition comprises by weight: 6-9 parts of Earthworm, 6-9 parts of Qianghuo, 6-9 parts of Caulis spatholobi, 3-5 parts of
Eucommia ulmoides, 3-5 parts of Phellodendron chinense, and 3-5 parts of Willow branch.
More preferably, the traditional Chinese medicinal composition comprises by weight: 8 parts of Earthworm, 8 parts of Qianghuo, 8 parts of Caulis spatholobi, 4 parts of Eucommia ulmoides, 4 parts of Phellodendron chinense, and 4 parts of Willow branch.
Further, the present invention provides a method for preparing the above-mentioned traditional Chinese medicinal composition, which includes the following steps:
Step 1. Weigh the components of the traditional Chinese medicine according to the dosage, as well as the auxiliary materials being 1-3 parts of filler, 1-2 parts of disintegrant and 0.2-1 parts of binder by weight, and crush them separately to obtain fine powders of each raw material;
Step 2: Mix the fine powder of the raw materials shown in Step 1 uniformly;
Step 3: Add 0.2-0.4 times the weight of ethanol to the mixed medicinal powder of Step 2 to prepare wet granules with a particle size of 10-30 mesh, dry and press.
Preferably, the auxiliary materials are 2 parts of filler, 1.5 parts of disintegrant and 0.6 parts of binder by weight;
Preferably, 0.3 times the weight of ethanol is added;
The filler is one or more of sorbitol, mannitol, starch, and polyethylene glycol; preferably sorbitol;
The disintegrant is one or more of sodium carboxymethyl cellulose, sodium starch, and sodium carboxymethyl starch, preferably sodium carboxymethyl cellulose;
The binder is gelatin.
Further, the present invention provides use of the above-mentioned traditional Chinese medicinal composition for preparing a medicine for treating rheumatic diseases.
Benefits:
Compared with the existing traditional Chinese medicinal composition for treating rheumatic diseases, the single Chinese medicines of the present invention have good compatibility and excellent therapeutic effect after compatibility. The pharmacodynamics of each component play a synergistic role, of which the clinically verified therapeutic effect is good, the curative effect is long-lasting, and the recurrence rate is low, it solves the problem of rheumatism diseases that cannot be cured for a long time. Additionally, the preparation method of the traditional Chinese medicinal composition of the present invention is simple, the efficacy of each component is maximized, the use safety is good, and it has a good clinical practice and social value.
DETAILED DESCRIPTION 1. Preparation Examples Preparation Example 1 The active ingredient of the raw material medicine is calculated by weight:
8 parts of Earthworm, 8 parts of Qianghuo, 8 parts of Caulis spatholobi, 4 parts of
Eucommia ulmoides, 4 parts of Phellodendron chinense, 4 parts of Willow branch
Step 1. Weigh the above-mentioned Chinese medicine components according to the dosage, and the auxiliary materials by weight: 2 parts of fi||er, 1.5 parts of disintegrant and 0.6 parts of binder, and crush them separately to obtain fine powders of each raw material;
Step 2: Mix the fine powder of the raw materials shown in Step 1 uniformly;
Step 3: Add 0.3 times the weight of ethanol to the mixed medicinal powder of step 2 to prepare wet granules with a particle size of 20 mesh, dry and press.
Preparation ExampleExcept for 5 parts of Earthworm, 5 parts of Qianghuo, 5 parts of Caulis spatholobi, 6 parts of Eucommia ulmoides, 6 parts of Phellodendron chinense, and 6 parts of Willow branch, the rest is the same as Preparation Example
Preparation ExampleExcept for 10 parts of Earthworm, 10 parts of Qianghuo, 10 parts of Caulis spatholobi, 2 parts of Eucommia ulmoides, 2 parts of Phellodendron chinense, and 2 parts of Willow branch, the rest is the same as Preparation Example
Preparation ExampleExcept for further adding 3 parts of Angelica sinensis, 4 parts of Rehmannia glutinosa, 3 parts of Cocklebur Seed, and 1.5 parts of Epimedium, the rest is the same as Preparation Example
Preparation ExampleExcept for further adding 2 parts of Angelica sinensis, 3 parts of Rehmannia glutinosa, 2 parts of Cocklebur Seed, and 1 part of Epimedium, the rest is the same as Preparation Example
Preparation ExampleExcept for further adding 4 parts of Angelica sinensis, 6 parts of Rehmannia glutinosa, 4 parts of Cocklebur Seed, and 2 parts of Epimedium, the rest is the same as Preparation Example
2. Examples of drug efficacy
The tablets prepared in the above preparation example 1 are subjected to clinical trials according to the following method
According to the latest Rheumatoid Arthritis (RA) diagnostic criteria of ACR/RULAR in 2009, 200 outpatient and inpatient cases are selected. According to the random method, they are divided into Preparation Example 1 and control group of 100 cases each. ln
Preparation Example 1, there are 50 females and 50 males aged from 22 to 80 years, with an average age of 40 years; the course of disease is 3 to 15 years. ln the control group, there are 50 females and 50 males aged from 21 to 78 years, with an average age of 38 years; the course of disease is 2 to 18 years. There is no significant difference between the t\No groups in terms of condition, gender, age, and course of disease.
All cases have scores above 6 points, which meets the latest RA diagnostic criteria. Exclusion criteria:
®Women under 21 years old, over 80 years old, pregnant or lactating. ®Combined with infectious diseases such as hepatitis B.
@Patients with allergies.
(Any case that meets any of the above items is an excluded case)
Treatment method
Control group: methotrexate tablets 7.5 mg/week, leflunomide 10 mg/day, sulfasalazine enteric-coated tablets 1.0 g/time, t\Nice a day.
ln the treatment group, besides the medicine of control group, the tablets of Preparation Example 1 were added, taken orally, 0.6 g each, 3 times a day, and the dosage was 3-4 tablets each time. 3 months is a course of treatment.
Observation indicators and methods
Refer to the "Guiding Principles for Clinical Research of New Chinese Medicines".
Significantly effective: the overall improvement rate of main symptoms and signs is 275%,
erythrocyte sedimentation rate and CRP are normal or significantly improved or close to normal; improved: the improvement rate of main symptoms and signs is 250%, erythrocyte sedimentation rate and CRP are improved; effective: the overall improvement rate of main symptoms and signs>30%, erythrocyte sedimentation rate and CRP have improved or no improvement; invalid: the improvement rate of main symptoms and signs is <30%, erythrocyte sedimentation rate and CRP have no improvement.
ln the treatment group (addition of the tablet group of preparation example 1), 43 cases are significantly effective, 33 cases are improved, 24 cases are effective, and 0 case is invalid, the significant effective rate is 43%, and the total effective rate was 100%; and in the control group, 27 cases are significantly effective, 35 cases are improved, 27 cases are effective, and 11 cases are invalid, the significant effective rate is 27%, and the total effective rate is 89%. The difference betvveen the two groups is very significant, and the treatment group is significantly better than the control group.
The traditional Chinese medicinal composition for treating rheumatism diseases of
the present invention and its preparation method have been described through specific examples. Those skilled in the art can learn from the content of the present invention and appropriately change the raw materials, process conditions and other links to achieve corresponding other objectives. All the related changes do not depart from the content of 5 the present invention, and all similar replacements and changes are obvious to those skilled in the art, and are deemed to be included in the scope of the present invention.
Claims (4)
1. A traditional Chinese medicinal composition for treating rheumatism diseases, characterized in that the traditional Chinese medicinal composition comprises by weight: 5-10 parts of Earthworm, 5-10 parts of Qianghuo, 5-10 parts of Caulis spatholobi, and 2-6 parts of Eucommia ulmoides, 2-6 parts of Phellodendron chinense, 2-6 parts of Willow branch.
2. The traditional Chinese medicinal composition according to claim 1, characterized in that the traditional Chinese medicinal composition comprises by weight: 6-9 parts of Earthworm, 6-9 parts of Qianghuo, 6-9 parts of Caulis spatholobi, 3-5 parts of Eucommia ulmoides, 3-5 parts of Phellodendron chinense, and 3-5 parts of Willow branch.
3. The traditional Chinese medicinal composition according to claim 1, characterized in that the traditional Chinese medicinal composition comprises by weight: 8 parts of Earthworm, 8 parts of Qianghuo, 8 parts of Caulis spatholobi, 4 parts of Eucommia ulmoides, 4 parts of Phellodendron chinense, and 4 parts of Willow branch.
4. Use of the traditional Chinese medicinal composition according to any one of claims 1-3 for preparing a medicine for treating rheumatic diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2150549A SE544963C2 (en) | 2021-04-30 | 2021-04-30 | A traditional Chinese medicinal composition for treating rheumatism diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2150549A SE544963C2 (en) | 2021-04-30 | 2021-04-30 | A traditional Chinese medicinal composition for treating rheumatism diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE2150549A1 SE2150549A1 (en) | 2022-10-31 |
| SE544963C2 true SE544963C2 (en) | 2023-02-14 |
Family
ID=84192142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE2150549A SE544963C2 (en) | 2021-04-30 | 2021-04-30 | A traditional Chinese medicinal composition for treating rheumatism diseases |
Country Status (1)
| Country | Link |
|---|---|
| SE (1) | SE544963C2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106267075A (en) * | 2016-08-31 | 2017-01-04 | 虞志秋 | A kind of Chinese medicinal capsule for treating ankylosing spondylitis |
| CN111973714A (en) * | 2020-09-09 | 2020-11-24 | 王景斌 | Traditional Chinese medicine composition and pill for treating rheumatism as well as preparation method and application of traditional Chinese medicine composition and pill |
-
2021
- 2021-04-30 SE SE2150549A patent/SE544963C2/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106267075A (en) * | 2016-08-31 | 2017-01-04 | 虞志秋 | A kind of Chinese medicinal capsule for treating ankylosing spondylitis |
| CN111973714A (en) * | 2020-09-09 | 2020-11-24 | 王景斌 | Traditional Chinese medicine composition and pill for treating rheumatism as well as preparation method and application of traditional Chinese medicine composition and pill |
Also Published As
| Publication number | Publication date |
|---|---|
| SE2150549A1 (en) | 2022-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101229300B (en) | Chinese traditional medicine preparation for treating bone fracture | |
| Rodda et al. | Investigation on anti-inflammatory property of Basella alba Linn leaf extract | |
| SE544963C2 (en) | A traditional Chinese medicinal composition for treating rheumatism diseases | |
| CN117257870A (en) | Composition for preventing and relieving sub-health of joints and preparation method thereof | |
| Atoe et al. | The Influence of Methanol Extracts of Some Plant Species Used in the Management of Pregnancy-Related Symptoms on the Reproductive Parameters of Pregnant Wistar Rats. | |
| KR20220105445A (en) | A traditional chinese medicinal composition for treating rheumatism diseases | |
| CN110623993A (en) | Compound nutritional tablet of traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| KR20220135784A (en) | A Method for Preparing Traditional Chinese Medicinal Composition | |
| KR20220120965A (en) | A traditional Chinsese medicinal composition for treating rheumatism diseases | |
| KR20220108450A (en) | A traditional chinese medicianl composition for treating rheumatism diseases | |
| CN105166550A (en) | Compound type feed additive for breeding boars and formula feed thereof | |
| KR20220106539A (en) | A traditional chinese medicinal composition for treating rheumatism diseases | |
| CN112972473B (en) | Medicine for treating adverse reactions of digestive tracts in radiotherapy and chemotherapy of tumors and preparation method thereof | |
| CN108743571A (en) | Prevent, treat the pharmaceutical composition and preparation method thereof of epilepsy | |
| KR20220129202A (en) | A traditional Chinese medicinal composition for treating rheumatism diseases | |
| DE102021101416A1 (en) | Traditional Chinese medicinal composition for treating rheumatism diseases | |
| DE102021107238A1 (en) | Traditional Chinese medicinal composition used to treat rheumatic diseases | |
| DE102021107236A1 (en) | Process for preparing a traditional Chinese medicinal composition | |
| DE102021100808A1 (en) | Traditional Chinese medicinal composition for the treatment of rheumatic diseases | |
| Ahmad et al. | DIURETIC ACTIVITY OF AQUEOUS EXTRACTS OF MICHELIA CHAMPACA L. LEAVES AD STEM BARK I RATS | |
| DE102021202701A1 (en) | TRADITIONAL CHINESE MEDICINAL COMPOSITION FOR THE TREATMENT OF RHEUMATIC DISEASES | |
| DE102021104979A1 (en) | Composition of traditional Chinese medicine for the treatment of rheumatic diseases | |
| AU2007201515B8 (en) | Natural Herbal Assistance | |
| El-Nabtity et al. | Antiurolithiatic effect of Cymbopogon Proximus, Alhagi Maurorum, on Sulfadimidine induced urolithiasis in male New Zealand rabbits | |
| DE102021103181A1 (en) | A traditional Chinese medicinal composition used to treat rheumatic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |